Renin-Angiotensin-System (RAS)-Acting Agents Market Insights Highlighting Opportunities Supporting Growth To 2030
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Anticipated Rise In Market Value Of The Renin-Angiotensin-System (RAS)-Acting Agents Market During The Forecast Period?
The renin-angiotensin-system (ras)-acting agents market size has experienced strong growth in recent years. It is forecast to increase from $6.11 billion in 2025 to $6.44 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.5%. This historical expansion can be attributed to several factors including the high prevalence of hypertension, the growth of the aging population, the widespread adoption of ACE inhibitors, enhanced cardiovascular screening, and the affordability of generic drugs.
The market for renin-angiotensin-system (ras)-acting agents is expected to undergo significant expansion in the coming years, with its size projected to reach $7.96 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.4%. This anticipated growth during the forecast period is driven by factors such as the increasing burden of chronic kidney disease, the demand for cardiometabolic drugs, improved patient adherence to treatment, expansion into emerging markets, and approvals for combination therapies. Furthermore, key trends for this period include the rising adoption of combination antihypertensive therapies, an increase in long-acting cardiovascular drugs, a greater focus on renal protection therapies, the expansion of generic RAS drug production, and a shift towards fixed-dose combinations.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23496&type=smp
Which Strong Drivers Are Impacting The Renin-Angiotensin-System (RAS)-Acting Agents Market Growth?
The expanding occurrence of high blood pressure is anticipated to propel the growth of the renin-angiotensin system (RAS)-acting agents market in the future. Hypertension, or elevated blood pressure, is a chronic medical condition characterized by a consistently excessive force of blood against artery walls. The prevalence of hypertension is increasing due to unhealthy dietary choices, particularly those high in salt and processed foods, which contribute to elevated blood pressure and strain on the cardiovascular system. Renin-angiotensin system (RAS)-acting agents help reduce hypertension by regulating blood pressure through the inhibition of angiotensin II, a hormone that constricts blood vessels and increases fluid retention, thereby promoting vasodilation and lowering blood pressure. For instance, in September 2025, according to the World Health Organization, a Switzerland-based intergovernmental organization, an estimated 1.4 billion adults aged 30–79 worldwide were living with hypertension in 2024, accounting for about 33% of people in this age group. Consequently, the rising prevalence of hypertension is driving the growth of the renin-angiotensin system (RAS)-acting agents market.
How Are Different Segments Classified In The Renin-Angiotensin-System (RAS)-Acting Agents Market Segment Analysis?
The renin-angiotensin-system (ras)-acting agents market covered in this report is segmented –
1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Renin Inhibitors, Aldosterone Antagonists, Other Drug Classes
2) By Indication: Hypertension, Heart Failure, Chronic Kidney Disease, Diabetic Nephropathy, Coronary Artery Disease
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics
4) By End-User: Hospitals, Research Institutes, Pharmaceutical Companies, Other End-Users
Subsegments:
1) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Captopril, Enalapril, Lisinopril, Ramipril, Perindopril
2) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan, Olmesartan, Telmisartan
3) By Renin Inhibitors: Aliskiren
4) By Aldosterone Antagonists: Spironolactone, Eplerenone
5) By Other Drug Classes: Dual Angiotensin Receptor-Neprilysin Inhibitors (ARNIs), Vasopeptidase Inhibitors, Mineralocorticoid Receptor Antagonists (MRAs), Angiotensin Receptor Blockers With Neprilysin Inhibitors (ARNBIs)
What Trends Are Transforming The Renin-Angiotensin-System (RAS)-Acting Agents Market?
Leading companies within the renin-angiotensin system (RAS)-acting agents market are concentrating on developing innovative renin-angiotensin system (RAS) inhibitors, including angiotensin-converting enzyme (ACE) inhibitors. This focus aims to boost efficacy, reduce adverse effects, enhance patient adherence, and address conditions such as hypertension, heart failure, and kidney diseases. An angiotensin-converting enzyme (ACE) inhibitor functions by lowering blood pressure through blocking the enzyme responsible for converting angiotensin I into angiotensin II, a substance known to constrict blood vessels. As an illustration, in November 2023, Proveca Ltd., a pharmaceutical firm based in the UK, secured a grant from the European Commission for pediatric use marketing authorization (PUMA) for its Aqumeldi (enalapril maleate) orodispersible tablets. These tablets are prescribed for managing heart failure in children ranging from birth to less than 18 years. Aqumeldi operates as an angiotensin-converting enzyme (ACE) inhibitor, treating young heart failure patients by inhibiting the angiotensin-converting enzyme (ACE), which prevents angiotensin I from transforming into angiotensin II, consequently relaxing blood vessels, enhancing blood flow, and lessening the strain on the heart.
Who Are The Companies Driving Activity In The Renin-Angiotensin-System (RAS)-Acting Agents Market?
Major companies operating in the renin-angiotensin-system (ras)-acting agents market are Novartis AG, AstraZeneca plc, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Pfizer Inc., Sanofi S.A., Bayer AG, Daiichi Sankyo Company Limited, Astellas Pharma Inc., Biocon Limited, Lupin Limited, Sun Pharmaceutical Industries Ltd., Mylan N.V., Zydus Lifesciences Limited
Get The Full Renin-Angiotensin-System (RAS)-Acting Agents Market Report:
Which Region Holds The Highest Market Share In The Renin-Angiotensin-System (RAS)-Acting Agents Market?
North America was the largest region in the renin-angiotensin-system (RAS)-acting agents market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the renin-angiotensin-system (ras)-acting agents market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Renin-Angiotensin-System (RAS)-Acting Agents Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Renin-Angiotensin-System (RAS)-Acting Agents Market 2026, By The Business Research Company
Angiotensin Receptor Blockers Arbs Market Report 2026
Angina Pectoris Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report
Inotropic Agents Market Report 2026
https://www.thebusinessresearchcompany.com/report/inotropic-agents-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
